Improving Clinician Confidence in Insulin Prescriptions at Discharge for Individuals With Newly Diagnosed Type 1

Haris Shoaib1, Yunus K Hussain1, Shahida Ahmed2

  • 1Medicine, Basildon and Thurrock University Hospital, Basildon, GBR.

Cureus
|September 18, 2023
PubMed

Insights

Pediatric doctors

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Clinical Quality Improvement

Background:

  • Low confidence in prescribing multiple daily injections (MDI) for pediatric type 1 diabetes mellitus (T1DM) identified among clinicians.
  • Existing local guidelines were perceived as inaccessible and not user-friendly.

Purpose of the Study:

  • To develop and evaluate tailored prescription guidance to enhance clinician confidence in MDI discharge prescriptions.
  • To improve the accuracy and accessibility of MDI prescribing information for pediatric doctors.

Main Methods:

  • Adapted existing local guidelines into a concise, practical MDI prescription tool with a checklist.
  • Intervention delivered to pediatric doctors in a single unit; confidence assessed via pre- and post-intervention questionnaires (Likert Scale).
  • Guidance disseminated via email and displayed prominently; feedback collected on accessibility and impact.

Main Results:

  • Confidence in MDI prescribing significantly increased from a mean score of 1.9 to 4.0 (p<0.0001).
  • 90% of doctors routinely consult guidelines, but 50% found them inaccessible.
  • 90% felt the new guidelines optimized patient care.

Conclusions:

  • Locally tailored, accessible MDI prescription guidance significantly boosts pediatric doctor confidence.
  • Adapted guidelines integrated into junior doctor induction and hospital intranet.
  • Continuous improvement and updates are planned to further enhance clinician confidence in T1DM management.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
309
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
225
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211